Retrospective Validation of Clinical Decision Support Tools for Predicting Effectiveness Outcomes in Inflammatory Bowel Disease Patients Treated with Vedolizumab.

Pharmaceutics · 2025 · PMC12845096 · PMID 41599122

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The rate of BioREM at week 54 also showed an increasing trend, but this difference was not statistically significant (21.4% vs. 58.8% p = 0.067).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.